LYSOGENE
LYS | PA
Overview
Corporate Details
- ISIN(s):
- FR0013233475
- LEI:
- 969500T64RILK1RD0852
- Country:
- France
- Address:
- 18 RUE JACQUES DULUD, 92200 NEUILLY-SUR-SEINE
- Website:
- https://www.lysogene.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease. Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders. Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-05-26 17:32 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 84.9 KB | |
| 2023-05-26 17:32 |
Delisting Announcement
Inside Information / Other news releases
|
English | 83.2 KB | |
| 2023-05-26 10:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 85.6 KB | |
| 2023-05-26 10:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 83.5 KB | |
| 2023-05-15 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 83.5 KB | |
| 2023-05-15 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 85.6 KB | |
| 2023-04-29 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 82.9 KB | |
| 2023-04-29 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 85.1 KB | |
| 2023-04-14 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 83.2 KB | |
| 2023-04-14 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 85.4 KB | |
| 2023-03-24 20:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 95.8 KB | |
| 2023-03-24 20:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 93.5 KB | |
| 2023-02-16 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 107.8 KB | |
| 2023-02-16 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 110.2 KB | |
| 2023-02-03 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 91.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Herantis Pharma Oyj | Finland | HRTIS | |
| Hiron-Trade Investments & Industrial Buildings Ltd. | Israel | HRON | ||
|
Human Stem Cells Institute PJSC | Russian Federation | ISKJ | |
|
Human Xtensions Ltd. | Israel | HUMX | |
|
Hybrigenics SA | France | ALHYG | |
|
Hyloris Pharmaceuticals SA | Belgium | HYL | |
|
Ikonisys S.A. | France | ALIKO | |
|
IMCB PJSC | Russian Federation | GEMA | |
|
Inify Laboratories AB | Sweden | INIFY | |
|
Innate Pharma | France | IPH |